Repligen Corp (RGEN)
Repligen makes bioprocessing equipment and consumables used to manufacture biological drugs. It last closed at $162.18 on Nov 17, down 0.37% on the day. The average 12-month price target from 4 analysts is $207.50 (+27.9% from the last close), with a high of $225.00 and a low of $180.00. Analyst consensus is Strong Buy, based on the latest ratings from 4 firms (3 buy, 1 hold, 0 sell). Over the past 90 days StreetAlpha recorded 1 whale options trade in RGEN, 0% of them bullish and 100% bearish. In the past 30 days there were 9 dark pool prints totaling $16.9M, the largest $3.2M.
Key Stats
Last 12 monthsNot reported for this period.
From RGEN's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Oct 30). Last 12 months adds up the four latest quarters.
Earnings
Full earnings history →Analyst Ratings & Price Targets
Analyst Ratings →Based on 4 analysts who set a price target on RGEN in the past 90 days. The average target is $207.50, with a high of $225.00 and a low of $180.00, compared with the last close of $162.18.
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Oct 28 | RBC Capital | Target raised | Buy | $160 → $200 |
| Oct 19 | Canaccord Genuity | Maintained | Hold | $180 |
| Oct 7 | Barclays | Maintained | Buy | $225 |
| Sep 9 | UBS | Maintained | Buy | $225 |
| Jul 30 | Wells Fargo | Maintained | Buy | $185 |
Technical Analysis
The stock is 8% below its 20 day and 9% below its 50 day average. It is 10% above its 200 day average, so the longer trend is still up. Momentum is weak (RSI 40). The nearest support is the swing low (Sep 10) at $161.14, and the nearest resistance the Pivot at $162.45.
| RSI (14) | 39.65 | Weak, oversold below 30 | Neutral |
| MACD | -3.29 | Below its signal line | Bearish |
| Stochastic | 6.9 | Near the bottom of its range | Oversold |
| ADX (14) | 13.7 | No clear trend | |
| Williams %R | -93.8 | Oversold below −80, overbought above −20 | Oversold |
| CCI (20) | -173.3 | Oversold below −100, overbought above 100 | Oversold |
| Rate of change | −9.0% | Change over 10 sessions | Bearish |
| ATR (14) | $7.68 | Typical daily range, 4.7% of price |
| RSI (14) | 50.64 | Middle of its range | Neutral |
| MACD | 8.22 | Below its signal line | Bearish |
| Stochastic | 31.0 | Middle of its range | Neutral |
| ADX (14) | 18.6 | No clear trend | |
| Williams %R | -88.6 | Oversold below −80, overbought above −20 | Oversold |
| CCI (20) | -23.3 | Oversold below −100, overbought above 100 | Neutral |
| Rate of change | −1.8% | Change over 10 sessions | Bearish |
| ATR (14) | $16.82 | Typical daily range, 10.4% of price |
What happened before
See how RGEN did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
Seasonality
How RGEN has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2006.
Whale Options Flow
90DNo whale options trades in RGEN in the last 90 days.
Dark Pool
30DRGEN Institutional Ownership
Full report →- ▲305 buying vs 192 selling
- ▲Held by funds +7.5 pts
- ▲Funds holding +43
- ▲Superinvestors: 3 added, 1 cut
- ●Put/call not meaningful
| Q3 2026 | This quarter | Last quarter | Change |
|---|---|---|---|
| Funds holding | 535 | 492 | +8.7% |
| In funds' top 10 | 11 | 5 | +120.0% |
| Held by funds | 127.7% | 120.2% | +7.5 pts |
| New / increased | 106 / 199 | 93 / 179 | +12.1% |
| Reduced / sold out | 135 / 57 | 143 / 59 | −5.0% |
| Put/call ratio | 8.61 | 7.77 | +10.8% |
From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.
AI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether RGEN is in one of them and how their past RGEN trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered RGEN in an article yet. Here's the latest on the wider market.
RGEN Congress Trades
All congress trades →| Person | Type | Amount | Traded | Filed | Delay |
|---|---|---|---|---|---|
| Donald J TrumpExecutive branch | Sell | $1K – $15K | May 22, 2026 | Jul 1, 2026 | 40 d |
| Lisa McClainR · MI | Sell | $1K – $15K | Oct 31, 2025 | Nov 21, 2025 | 21 d |
| Lisa McClainR · MI | Sell | $1K – $15K | Oct 30, 2025 | Nov 21, 2025 | 22 d |
| Lisa McClainR · MI | Buy | $1K – $15K | Oct 30, 2025 | Nov 21, 2025 | 22 d |
| Lisa McClainR · MI | Buy | $1K – $15K | Jul 22, 2025 | Aug 13, 2025 | 22 d |
Members of Congress and senior officials report trades up to 45 days later, as dollar ranges. Filings show a trade happened, not why. Not investment advice.
About Repligen
Repligen is a life sciences company based in Waltham, Massachusetts, that makes equipment and consumables used to manufacture biological drugs. Its product lines cover filtration, chromatography, process analytics and proteins, including filters, tangential flow systems, columns that come already packed with resin, and fluid management parts. Its main customers are drug developers, contract manufacturers and other life science companies that make antibody-based drugs, vaccines, and cell and gene therapies.
- Headquarters
- Waltham, MA






